Fc engineering is a promising approach to enhance the antitumor efficacy of monoclonal
antibodies (mAbs) through antibody-dependent cell-mediated cytotoxicity (ADCC). Glyco …

Antibody-dependent cellular cytotoxicity (ADCC) is mediated through the engagement of the
Fc segment of antibodies with Fcγ receptors (FcγRs) on immune cells upon binding of tumor …

Enhancing the effector function by optimizing the interaction between Fc and Fcγ receptor
(FcγR) is a promising approach to enhance the potency of anticancer monoclonal antibodies …

Abstract Engaging inhibitory FcγRIIb by Fc region has been recently reported to be an
attractive approach for improving the efficacy of antibody therapeutics. However, the …

While glyco-engineered monoclonal antibodies (mAbs) with improved antibody-dependent
cell-mediated cytotoxicity (ADCC) are reaching the market, extensive efforts have also been …

Background: Engineering of the antibody's fragment crystallizable (Fc) by modifying the
amino acid sequence (Fc protein engineering) or the glycosylation pattern (Fc glyco …

We previously reported that chimeric monoclonal antibodies (mAbs) with tandemly repeated
Fc domains, which were developed by introducing tandem repeats of Fc domains …

Antibody-based therapeutics has emerged as a major tool in cancer treatment. Guided by
the superb specificity of the antibody variable domain, it allows the precise targeting of …

In the last two decades, monoclonal antibodies have revolutionized the therapy of cancer
patients. Although antibody therapy has continuously been improved, still a significant …

Today, monoclonal immunoglobulin gamma (IgG) antibodies have become a major option in
cancer therapy especially for the patients with advanced or metastatic cancers. Efficacy of …